Search
01/11/2025
Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma
Vilaseca, VG, Perez, ES, Fabrego, IE, Peral, IL, Prat, AM. Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma. MEDICINA CLINICA. 2025; 165(5)DOI:10.1016/j.medcli.2025.107073. PMID:40543401. IF:2.100(Q2/3D).
01/10/2025
Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis
Fasanella, MG, Mozos, A, Briones, J, Nomdedeu, JF, Novelli, S. Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis. Cancer Reports. 2025; 8(10)DOI:10.1002/cnr2.70356. PMID:41031578. IF:(Q/D).
01/10/2025
Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study
Tolosa-Ridao, C, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaria, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, García, II, Ribes-Amorós, J, Lavilla, E, Lopez-Marín, J, Basalobre, P, Filaferro, S, Cedillo, A, Bento, L, Sureda, A, Salas, MQ. Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study. BRITISH JOURNAL OF HAEMATOLOGY. 2025; 207(4)DOI:10.1111/bjh.70068. PMID:40796522. IF:3.800(Q1/3D).
30/09/2025
Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma
Osuna-Gómez, R, López-Pardo, J, Mulet, M, Nomdedéu, J, Cantó, E, Ortin, R, Cayuela, AS, Ortiz, MA, Guinart-Cuadra, A, Vidal, S. Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma. Pharmaceutics. 2025; 17(10)DOI:10.3390/pharmaceutics17101278. PMID:41155915. IF:5.500(Q1/1D).
26/09/2025
Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation
Torrent-Rodríguez, A, Cascos, E, Garcés, VN, Pérez-López, E, Baile-González, M, Rodríguez, CM, Cascón, MJP, Luque, M, Esquirol, A, Calvo, CM, Peña-Muñoz, F, Fernando, IH, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Lorenzo, JLL, Girón, MFD, Pinedo, LG, García-Maño, L, González-Rodriguez, AP, Torrado, T, Filaferro, S, Basalobre, P, Ortí, G, Rovira, M, Chacón, MJ, Salas, MQ. Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers. 2025; 17(19)DOI:10.3390/cancers17193128. PMID:41097656. IF:4.400(Q2/3D).
22/09/2025
Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis
Lewis, JFM, Daver, NG, Robinson, NJ, Pandya, BJ, Pierre-Louis, B, Monir, S, Sierra, J. Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis. Cancer Medicine. 2025; 14(18)DOI:10.1002/cam4.71205. PMID:40981231. IF:3.100(Q2/5D).
01/09/2025
Clinical characteristic and outcome of HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: A study of Infectious Disease Working Party of EBMT
Perruccio, K, Ward, KN, Tridello, G, Knelange, N, Zeiser, R, Franke, GN, Sirvent, A, Einsele, H, Vicent, MG, Navarro, JMF, Contentin, N, Collin, M, Martino, R, Gambella, M, Sengeloev, H, Passweg, J, Snowden, J, Nagler, A, Kulagin, A, Gabriel, M, Kröger, N, Cascon, MJP, Yeshurun, M, Güngör, T, Robin, C, Clark, A, Duarte, ML, Amor, AA, Itala-Remes, M, Mikulska, M, Styczynski, J, de la Camara, R, Ljungman, P, Averbuch, D, Cesaro, S. Clinical characteristic and outcome of HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: A study of Infectious Disease Working Party of EBMT. BONE MARROW TRANSPLANTATION. 2025; 60(9)DOI:10.1038/s41409-025-02638-7. PMID:40461849. IF:5.200(Q1/1D).
01/09/2025
Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Follow-Up
Fernandez, RA, Arroyo, A, Cedena, MT, Rosiñol, L, De la Rubia, J, Miqueleiz, S, González-Calle, V, de Arriba, F, Casado-Montero, F, Hernandez, MT, Mas, M, Fernandez-Abellan, P, Rodriguez-Otero, P, Calle, C, Abella, E, Ribas, P, Alegre, A, Bergua, JM, Ocio, E, De la Cruz, J, Mateos, MV, San-Miguel, J, Bladé, J, Lahuerta, JJ, Martinez-Lopez, J. Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Follow-Up. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).